News Quantified

VTGN – vistagen therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference [Yahoo! Finance]

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression [Seeking Alpha]

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

5.1%

BEAT

Form 8-K Vistagen Therapeutics, For: Apr 25

Form DEF 14A Vistagen Therapeutics, For: May 29

Form PRE 14A Vistagen Therapeutics, For: May 29

Form 8-K Vistagen Therapeutics, For: Apr 01

Form 4 Vistagen Therapeutics, For: Mar 04 Filed by: Cunningham Ann Michelle

Top News Gainers

12/10 U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder 26.5%

3/25 VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million 24.6%

12/12 Form 8-K VistaGen Therapeutics, For: Dec 10 23.7%

7/23 VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray 11.1%

4/27 Form 4 VistaGen Therapeutics, For: Apr 23 Filed by: Underdown Brian J. 8.7%

11/8 Form 8-K VistaGen Therapeutics, For: Nov 07 8.0%

1/31 Form 8-K VistaGen Therapeutics, For: Jan 30 7.2%

8/1 Vistagen Therapeutics Inc (NASDAQ: VTGN) had its "neutral" rating re-affirmed by analysts at Chardan Capital. 6.3%

10/11 Vistagen Therapeutics Inc (NASDAQ: VTGN) was given a new $4.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 5.8%

12/12 Form D VistaGen Therapeutics, 5.4%

Top News Decliners

11/14 VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder -72.7%

2/11 VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects -24.4%

2/20 VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder -21.6%

10/1 Form S-8 POS VistaGen Therapeutics, -15.9%

1/30 VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients -14.5%

12/28 Vistagen Therapeutics Inc (NASDAQ: VTGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -12.1%

4/15 Form 424B3 VistaGen Therapeutics, -11.8%

2/13 Form 10-Q VistaGen Therapeutics, For: Dec 31 -10.9%

10/9 Form 8-K VistaGen Therapeutics, For: Oct 08 -10.5%

7/23 Form DEF 14A VistaGen Therapeutics, For: Jul 26 -10.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day